NewAmsterdam Pharma (NAMS) News Today $18.57 -0.43 (-2.26%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$18.78 +0.21 (+1.13%) As of 02/21/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period TimesSquare Capital Management LLC Buys 640,329 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)TimesSquare Capital Management LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 250.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 895,574 shares of the company's stockFebruary 20 at 4:46 AM | marketbeat.comNewAmsterdam Pharma (NAMS) Projected to Post Quarterly Earnings on WednesdayNewAmsterdam Pharma (NASDAQ:NAMS) will be releasing earnings before the market opens on Wednesday, February 26.February 19 at 4:10 AM | marketbeat.comRA CAPITAL MANAGEMENT, L.P. Expands Stake in NewAmsterdam Pharma Co NVFebruary 15, 2025 | gurufocus.comAndreas Halvorsen Reduces Stake in NewAmsterdam Pharma Co NVFebruary 15, 2025 | gurufocus.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Rating of "Buy" by BrokeragesNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has earned a consensus recommendation of "Buy" from the six analysts that are covering the stock, MarketBeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that haFebruary 14, 2025 | marketbeat.comabrdn plc Increases Stake in NewAmsterdam Pharma (NASDAQ:NAMS)abrdn plc grew its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 38.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 179,060 shares of the company's stock after purchasing an additional 50,000 shares during thFebruary 10, 2025 | marketbeat.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options for New HiresFebruary 7, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comJennison Associates LLC Raises Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Jennison Associates LLC increased its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 291.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,998,541 shares of the company's stock afFebruary 4, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Buys New Position in NewAmsterdam Pharma (NASDAQ:NAMS)China Universal Asset Management Co. Ltd. purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,589 sharFebruary 3, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Trading Up 4.1% - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.1% Higher - Still a Buy?January 31, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Bought by JPMorgan Chase & Co.JPMorgan Chase & Co. raised its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 176.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,351 shares of the company's stock after buyJanuary 30, 2025 | marketbeat.comNewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech ConferenceJanuary 29, 2025 | markets.businessinsider.comNewamsterdam pharma CFO sells shares worth $1.5 millionJanuary 29, 2025 | msn.comNewAmsterdam Pharma Co NV (NAMS) Announces CFO's Participation in Guggenheim SMID Cap Biotech ...January 29, 2025 | gurufocus.comMoody Aldrich Partners LLC Sells 137,348 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Moody Aldrich Partners LLC trimmed its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 63.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,145 shares of the company's stock after selling 137,348 shareJanuary 29, 2025 | marketbeat.comNewAmsterdam Pharma's SWOT analysis: obicetrapib stock shows promise amid trialsJanuary 29, 2025 | msn.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Time to Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's What HappenedJanuary 28, 2025 | marketbeat.comDeep Dive Into NewAmsterdam Pharma Stock: Analyst Perspectives (8 Ratings)January 24, 2025 | benzinga.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Outperform Rating at Royal Bank of CanadaRoyal Bank of Canada restated an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research report on Friday.January 24, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received a consensus rating of "Buy" from the six brokerages that are currently covering the stock, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month target price among analysts thatJanuary 20, 2025 | marketbeat.comBuy Recommendation for NewAmsterdam Pharma: Strong Potential of Obicetrapib Backed by Positive Phase 3 Trial Results and Market PositioningJanuary 17, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Price Down 4.9% - Should You Sell?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Down 4.9% - What's Next?January 16, 2025 | marketbeat.comNewAmsterdam Pharma Company N.V. (NAMS): Analysts Recommend This 52-Week High Stocks NowJanuary 15, 2025 | insidermonkey.comPromising Outlook for NewAmsterdam Pharma: Ed Arce’s Buy Rating Backed by Strategic Developments and Phase 3 SuccessesJanuary 14, 2025 | markets.businessinsider.comNewAmsterdam Pharma (NASDAQ:NAMS) Earns "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday.January 14, 2025 | marketbeat.comNewAmsterdam Pharma outlines 2025 strategic prioritiesJanuary 11, 2025 | markets.businessinsider.comNewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic PrioritiesJanuary 10, 2025 | gurufocus.comNewAmsterdam Pharma Co NV (NAMS) Announces Inducement Share Options and Restricted Stock Units ...January 9, 2025 | gurufocus.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 9, 2025 | globenewswire.comNewAmsterdam Pharma (NASDAQ:NAMS) Reaches New 1-Year High - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 52-Week High - Time to Buy?January 8, 2025 | marketbeat.comState Street Corp Buys 23,805 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)State Street Corp raised its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 168.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,915 shares of the company's stocJanuary 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 29,846 SharesJanuary 3, 2025 | insidertrades.comNap B.V. Forgrowth Sells 29,846 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 29,846 shares of the company's stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $25.54, for a total transaction of $762,266.84. Following the transaction, the insider now owns 10,656,172 shares in the company, valued at $272,158,632.88. This represents a 0.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.January 2, 2025 | marketbeat.comFY2024 Earnings Estimate for NAMS Issued By HC WainwrightNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for NewAmsterdam Pharma in a research report issued on Monday, December 30th. HC Wainwright analyst E. Arce anticipates that the company will post earnings of ($1.64)January 1, 2025 | marketbeat.comHC Wainwright & Co. Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationDecember 31, 2024 | msn.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Nap B.V. Forgrowth Sells 33,438 SharesDecember 31, 2024 | insidertrades.comNewAmsterdam Pharma initiated with a Buy at H.C. WainwrightDecember 30, 2024 | markets.businessinsider.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,438 Shares of StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 33,438 shares of NewAmsterdam Pharma stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $26.01, for a total value of $869,722.38. Following the transaction, the insider now owns 10,727,490 shares in the company, valued at approximately $279,022,014.90. This represents a 0.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.December 30, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at HC WainwrightHC Wainwright began coverage on NewAmsterdam Pharma in a research note on Monday. They set a "buy" rating and a $48.00 price objective for the company.December 30, 2024 | marketbeat.comNap B.V. Forgrowth Sells 25,132 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockDecember 27, 2024 | insidertrades.comNewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells $640,614.68 in StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 25,132 shares of the company's stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $25.49, for a total transaction of $640,614.68. Following the sale, the insider now directly owns 10,777,092 shares of the company's stock, valued at $274,708,075.08. This represents a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.December 26, 2024 | marketbeat.comNap B.V. Forgrowth Sells 49,772 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 49,772 shares of the company's stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $25.60, for a total transaction of $1,274,163.20. Following the completion of the transaction, the insider now owns 10,802,224 shares of the company's stock, valued at approximately $276,536,934.40. The trade was a 0.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.December 26, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of "Buy" by AnalystsNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has received a consensus recommendation of "Buy" from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year target priDecember 26, 2024 | marketbeat.comInsider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 100,728 Shares of StockDecember 21, 2024 | insidertrades.comNap B.V. Forgrowth Sells 100,728 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) StockNewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 100,728 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the transaction, the insider now owns 10,908,502 shares in the company, valued at approximately $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.December 20, 2024 | marketbeat.comWhat is Leerink Partnrs' Estimate for NAMS Q1 Earnings?NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of NewAmsterdam Pharma in a report released on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings of ($0.20) peDecember 20, 2024 | marketbeat.comQ4 Earnings Forecast for NAMS Issued By Leerink PartnrsNewAmsterdam Pharma (NASDAQ:NAMS - Free Report) - Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for NewAmsterdam Pharma in a report issued on Tuesday, December 17th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings of (December 19, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - What's Next?NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down - Here's What HappenedDecember 18, 2024 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Up 4.7% - Time to Buy?NewAmsterdam Pharma (NASDAQ:NAMS) Trading 4.7% Higher - Still a Buy?December 17, 2024 | marketbeat.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼0.710.60▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼44▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Revolution Medicines News Legend Biotech News BridgeBio Pharma News Axsome Therapeutics News Blueprint Medicines News Telix Pharmaceuticals Limited American Depositary Shares News Elanco Animal Health News Lantheus News Nuvalent News Cytokinetics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
